Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOACs vs LMWH/Warfarin for VTE in Cancer (CANVAS)
NCT02744092Completed
- Sponsor
- Alliance Foundation Trials
- Start
- Dec 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivaroxaban, apixaban, edoxaban and dabigatran in venous thromboembolism (VTE) (4 arms), sponsored by Alliance Foundation Trials. Primary endpoint: Cumulative Non-Fatal VTE Recurrence at 6 months. Started Dec 2016; status: completed.
02
Drugs
rivaroxabanapixabanedoxabandabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02744092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02744092.